Status:
ACTIVE_NOT_RECRUITING
Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG
Lead Sponsor:
DurVena, Inc.
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surg...
Detailed Description
The Photochemical Tissue Passivation (PTP) treatment of a saphenous vein graft (SVG) is indicated for the reduction of intimal hyperplasia and graft failure rate in SVGs after coronary bypass graft (C...
Eligibility Criteria
Inclusion
- Signed informed consent, inclusive of release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation.
- Age 21 years or older.
- Planned and scheduled on-pump, arrested heart CABG.
- Two or more vein grafts to native vessels having at least 75% stenosis and comparable runoff.
- IMA graft indicated for the LAD.
- Appropriately sized and accessible target coronary arteries, with a minimum diameter of 2 mm and adequate vascular bed (without significant distal stenosis), as assessed by pre-operative cardiac angiography and verified by diameter gauging intraoperatively.
- \-
Exclusion
- Concomitant non-CABG cardiac surgical procedure.
- Prior cardiac surgery.
- Emergency CABG surgery (e.g., cardiogenic shock, inotropic pressure support, intraaortic balloon pump, ECMO).
- Contraindication for on-pump CABG with cardioplegic arrest (e.g., severely calcified aorta).
- Calcification at the intended anastomotic sites, as assessed upon opening of the chest and before randomization.
- Platelets \< 50,000/mm3 or other evidence of coagulopathy, INR greater than 1.5 in the absence of anticoagulation therapy.
- Infection (WBC ≥12.5 x 103/ml and or temperature ≥100.5°F/38°C).
- History of cerebral vascular accident (CVA) or transient ischemic attacks (TIA) within the last 3 months.
- Unwilling or unable to receive blood transfusion.
- Inability to undergo treatment with heparin.
- Participants on dialysis or GFR of \<30 ml/min/1.73m2.
- Primary liver disease with bilirubin, SGOT, or SGPT \> 4X upper limit of normal.
- Prior history of allergic reaction to contrast media with anaphylaxis or severe peripheral edema.
- Any medical condition that, in the opinion of the investigator, would compromise the safety of the participant or quality of the study data.
- Pregnancy and nursing or lactating.
- Current, or past participation in a clinical trial within the past 30 days.
Key Trial Info
Start Date :
January 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2025
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT06150872
Start Date
January 8 2024
End Date
March 30 2025
Last Update
October 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Republican Scientific Center of Emergency Medical Care
Tashkent, Uzbekistan